The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
López A, Zobolas J, Dumontier T, Aittokallio T(2026) Multi-modal learning with incomplete data Nat Commun, 17(1) DOI 10.1038/s41467-026-77212-w, PubMed 42811071
Yaqub S, Valberg M, Bjørnbeth BA, Angelsen JH, Brudvik KW, Eilertsen IA, Fristedt R, Fristrup CW, Gilg S, Hemmingsson O, Isaksson B, Juel IS, Knudsen AR, Larsen PN, Mortensen KE, Olsen IC, Sandström P, Sandvik OM, Sparrelid E, Taflin H, Lothe RA, Taskén K, ASAC Study Group(2026) Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial Lancet Gastroenterol Hepatol(in press) DOI 10.1016/S2468-1253(26)00260-8, PubMed 42777749
Avershina E, Birkeland EE, Bucher-Johannessen C, Rounge TB(2026) CRISPR-Cas immune repertoires as an ecological record of bacterial interactions with mobile genetic elements in the human gut Gut Microbes, 18(1), 2734649 DOI 10.1080/19490976.2026.2734649, PubMed 42768305
Spangenberg H, Moe EL, Ødegård Fougner Ø, Sneeggen M, Pan M, Tan KW, Mateo Tortola M, Valenzuela C, Chang YY, Stenmark H, Raiborg C, Schink KO(2026) A phosphoinositide and RAB switch controls early macropinocytosis J Cell Sci(in press) DOI 10.1242/jcs.265349, PubMed 42852846
Forcados C, Köksal H, Scherer E, Abrantes R, Dillard P, Duarte HO, Josefsson S, Gomes C, de Montlaur C, Hellesøy HTZ, Dunkel R, Smeland EB, Myklebust JH, Reis CA, McCormack E, Gelebart P, Inderberg EM, Wälchli S(2026) Reviving low-affinity glycan-targeting CAR with combinatorial design Cell Rep Med, 103108(in press) DOI 10.1016/j.xcrm.2026.103108, PubMed 42849448
Schuster C, Oppedal IA, Vinnem LI, Abrahamsson EL, Barrett TM, Steinskog ESS, Giercksky Russnes HE, Helland Å(2026) Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report Acta Oncol, 65, 814-817 DOI 10.2340/1651-226X.2026.46424, PubMed 42820355